nach oben

Erschienen in:

2021 | OriginalPaper | Buchkapitel

OAB und Dranginkontinenz

verfasst von : Andreas Wiedemann

Erschienen in: Medikamente in der Urologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die „International Continence Society“ ICS weist in ihrem seit 2003 international anerkannten Klassifikationssystem 5 Harninkontinenzformen auf: die Belastungsinkontinenz, Überaktive Blase, Überlaufinkontinenz, neurogene Inkontinenz und extraurethrale Inkontinenz. Die genannten Typologien treten nicht immer klar voneinander getrennt auf; vor allem altersphysiologische, elektronenmikroskopisch nachweisbare Detrusorveränderungen, mit zunehmendem Alter auftretende, die Kontinenzlage störende Komorbiditäten innerhalb und außerhalb des Harntraktes wie z. B. der Diabetes mellitus lassen das Bild der Harninkontinenz vor allem bei älteren, geriatrischen Patienten komplex erscheinen. Hier sei auf entsprechende Leitlinien verwiesen.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37–49PubMedCrossRef

Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V (2006) Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 13:692–698PubMedCrossRef

Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, et al (2014) Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). Eur Urol

Abrams P, Kelleher C, Staskin D, Kay R, Martan A et al (2017) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol 35:827–838PubMedCrossRef

Alcantara-Montero A (2016) Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study). Actas Urol Esp 40:593–594PubMed

Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N et al (2001) Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 76:358–363PubMedCrossRef

Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP (2006) Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 17:502–511PubMedCrossRef

Arbeitsgruppe Inkontinenz der DGG: Klaus Becher BBSESvdHRK-HAWFGDGfG (2019) [Urinary incontinence in geriatric patients: diagnosis and therapy]. Aktuelle Urol

A W, I F. (2008) LUTS bei Typ-2-Diabetikern – die Wittener Diabetes-Erhebung. Rep Eur J Geriatrics 10 (2008)

Barendrecht MM, Oelke M, Laguna MP, Michel MC (2007) Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 99:749–752PubMedCrossRef

Barkin J, Corcos J, Radomski S, Jammal MP, Miceli PC et al (2004) A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 26:1026–1036PubMedCrossRef

Boy S, Reitz A, Wirth B, Knapp PA, Braun PM et al (2006) Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women. Eur Urol 50:119–125PubMedCrossRef

Cardozo L, Chapple CR, Toozs-Hobson P, Grosse-Freese M, Bulitta M et al (2000) Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85:659–664PubMedCrossRef

Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS et al (2011) A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72:235–246PubMedPubMedCentralCrossRef

Cardozo L, Drutz HP, Baygani SK, Bump RC (2004a) Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 104:511–519PubMedCrossRef

Cardozo L, Lisec M, Millard R, van Vierssen TO, Kuzmin I et al (2004b) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924PubMedCrossRef

Cardozo L, Hessdorfer E, Milani R, Arano P, Dewilde L et al (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 102:1120–1127PubMedCrossRef

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310PubMedCrossRef

Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMedCrossRef

Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296–305PubMedCrossRef

Chapple C, Khullar V, Nitti VW, Frankel J, Herschorn S, et al (2014) Efficacy of the beta3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. Eur Urol

Corcos J, Casey R, Patrick A, Andreou C, Miceli PC et al (2006) A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 97:520–527PubMedCrossRef

Diefenbach K, Donath F, Maurer A, Quispe BS, Wernecke KD et al (2003) Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 23:395–404PubMedCrossRef

Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I (2005) Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int 95:346–349PubMedCrossRef

Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR et al (2002) Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 168:580–586PubMedCrossRef

Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2003) Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263PubMedCrossRef

Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW (2005) Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 23:263–270PubMedCrossRef

Dmochowski RR, Sand PK, Zinner NR, Staskin DR (2008) Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 71:449–454PubMedCrossRef

Donnellan CA, Fook L, McDonald P, Playfer JR (1997) Oxybutynin and cognitive dysfunction. BMJ 315:1363–1364PubMedPubMedCentralCrossRef

Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G et al (2000) Efficacy and cardiac safety of propiverine in elderly patients – a double-blind, placebo-controlled clinical study. Eur Urol 37:702–708PubMedCrossRef

Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S (1999) Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 10:283–289PubMedCrossRef

Elbadawi A, Yalla SV, Resnick NM (1993a) Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 150:1668–1680PubMedCrossRef

Elbadawi A, Yalla SV, Resnick NM (1993b) Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 150:1657–1667PubMedCrossRef

Elbadawi A, Yalla SV, Resnick NM (1993c) Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 150:1681–1695PubMedCrossRef

Ferrara P, D’Aleo CM, Tarquini E, Salvatore S, Salvaggio E (2001) Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int 87:674–678PubMedCrossRef

Finkbeiner AE (1985) Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 134:443–449PubMedCrossRef

Fink KG, Huber J, Wurnschimmel E, Schmeller NT (2008) The use of Duloxetine in the treatment of male stress urinary incontinence. Wien Med Wochenschr 158:116–118PubMedCrossRef

Gajewski JB, Awad SA (1986) Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J. Urol 135:966–968PubMedCrossRef

Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD et al (2005) A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J. Urol 173:1647–1653PubMedCrossRef

Groen-Wijnberg M, van Dijk J, Krauwinkel W, Kerbusch V, Meijer J et al (2017) Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Eur J Drug Metab Pharmacokinet 42:417–429PubMedCrossRef

Gulsun M, Pinar M, Sabanci U (2006) Psychotic disorder induced by oxybutynin: Presentation of two cases. Clin Drug Investig 26:603–606PubMedCrossRef

Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45:420–429PubMedCrossRef

Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M et al (2013) A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82:313–320PubMedCrossRef

Hesch K (2007) Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 20:307–314

Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M et al (2008) Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. Curr Med Res Opin 24:3513–3521PubMedCrossRef

Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ (2010) Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 109:702–708PubMedCrossRef

Homma Y, Paick JS, Lee JG, Kawabe K (2003) Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 92:741–747PubMedCrossRef

Hughes KM, Lang JC, Lazare R, Gordon D, Stanton SL et al (1992) Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22:859–869PubMedCrossRef

Hill S, Khullar V, Wyndaele JJ, Lheritier K (2006) Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17:239–247PubMedCrossRef

Holmes DM, Montz FJ, Stanton SL (1989) Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial. Br J Obstet Gynaecol 96:607–612PubMedCrossRef

Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M et al (2002) M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 366:97–103PubMedCrossRef

Ivchenko A, Bodeker RH, Neumeister C, Wiedemann A (2018) Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study. BMC Urol 18:80PubMedPubMedCentralCrossRef

Jonas U, Hofner K, Madersbacher H, Holmdahl TH (1997) Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol 15:144–151PubMedCrossRef

Junemann KP, Halaska M, Rittstein T, Murtz G, Schnabel F et al (2005) Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 48:478–482PubMedCrossRef

Junemann KP, Hessdorfer E, Unamba-Oparah I, Berse M, Brunjes R et al (2006) Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int 77:334–339PubMedCrossRef

Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z (2006) Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68:328–332PubMedCrossRef

Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J (2011) Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 107:1432–1440PubMedCrossRef

Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z (2012) Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int 109:1831–1840PubMedCrossRef

Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73:14–18PubMedCrossRef

Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K (1998) Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46:8–13PubMedCrossRef

Kay G, Crook T, Rekeda L, Lima R, Ebinger U et al (2006) Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50:317–326PubMedCrossRef

Lee KS, Lee HW, Choo MS, Paick JS, Lee JG et al (2010) Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data’. BJU Int 105:1565–1570PubMedCrossRef

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T et al (2013) Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig 33:429–440PubMedCrossRef

Lipton RB, Kolodner K, Wesnes K (2005) Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 173:493–498PubMedCrossRef

MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR (2005) Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 174:1301–1305PubMedCrossRef

Madersbacher H, Stohrer M, Richter R, Giannetti BM, Murtz G (1991) High-dose trospium chloride in therapy of detrusor hyperreflexia. Urologe A 30:260–263PubMed

Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G (1995) Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 75:452–456PubMedCrossRef

Malhotra B, Darsey E, Crownover P, Fang J, Glue P (2011a) Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol 72:226–234PubMedPubMedCentralCrossRef

Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X et al (2011b) Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol 72:263–269PubMedPubMedCentralCrossRef

Manjunatha R, Pundarikaksha HP, Hanumantharaju BK, Anusha SJ (2015) A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder. J Clin Diagn Res 9:FC05–9

Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144:1089–1099PubMedPubMedCentralCrossRef

Mansfield KJ, Chandran JJ, Vaux KJ, Millard RJ, Christopoulos A et al (2009) Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther 328:893–899PubMedCrossRef

Mazur D, Gocking K, Wehnert J, Schubert G, Herfurth G, Alken RG (1994) Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence. A multicenter study for optimizing dosage. Urologe A 33:447–452PubMed

Metello J, Nogueira B, Torgal M, Colaco J, Vieira A et al (2007) Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J Pelvic Floor, DysfunctCrossRef

Moisey CU, Stephenson TP, Brendler CB (1980) The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 52:472–475PubMedCrossRef

Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev:CD003781

Nilvebrant L, Hallen B, Larsson G (1997) Tolterodine–a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 60:1129–1136PubMedCrossRef

Nitti VW, Chapple CR, Walters C, Blauwet MB, Herschorn S et al (2014) Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Int J Clin Pract 68:972–985PubMedCrossRef

Norton PA, Zinner NR, Yalcin I, Bump RC, Duloxetine Urinary Incontinence Study G (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40–48CrossRef

Oreskovic S, But I, Banovic M, Goldstajn MS (2012) The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Coll Antropol 36:243–248PubMed

Pietzko A, Dimpfel W, Schwantes U, Topfmeier P (1994) Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 47:337–343PubMedCrossRef

Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R (2006) Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 67:275–280PubMedCrossRef

Sand P, Zinner N, Newman D, Lucente V, Dmochowski R et al (2007) Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 99:836–844PubMedCrossRef

Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW (2009a) Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 20:827–835PubMedCrossRef

Sand PK, Dmochowski RR, Zinner NR, Staskin DR, Appell RA (2009b) Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 20:1431–1438PubMedCrossRef

Sathyan G, Chancellor MB, Gupta SK (2001) Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 52:409–417PubMedPubMedCentralCrossRef

Stahl MM, Ekstrom B, Sparf B, Mattiasson A, Andersson KE (1995) Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 14:647–655PubMedCrossRef

Staskin DR, Harnett MD (2004) Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 5:423–426PubMedCrossRef

Staskin DR, Te AE (2006) Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 97:1256–1261PubMedCrossRef

Staskin D, Kay G, Tannenbaum C, Goldman HB, Bhashi K et al (2010) Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 58:1618–1619PubMedCrossRef

Staskin D, Khullar V, Michel MC, Morrow JD, Sun F et al (2011) Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 30:1480–1485PubMedCrossRef

Stohrer M, Bauer P, Giannetti BM, Richter R, Burgdorfer H, Murtz G (1991) Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 47:138–143PubMedCrossRef

Tapp AJ, Cardozo LD, Versi E, Cooper D (1990) The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 97:521–526PubMedCrossRef

Thompson IM, Lauvetz R (1976) Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology 8:452–454PubMedCrossRef

Thor KB, de Groat WC (2010) Neural control of the female urethral and anal rhabdosphincters and pelvic floor muscles. Am J Physiol Regul Integr Comp Physiol 299:R416–R438PubMedPubMedCentralCrossRef

Thuroff JW, Bunke B, Ebner A, Faber P, de GP, et al (1991) Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145:813–816PubMedCrossRef

Todorova A, Vonderheid-Guth B, Dimpfel W (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41:636–644PubMedCrossRef

Valsecia ME, Malgor LA, Espindola JH, Carauni DH (1998) New adverse effect of oxybutynin: “night terror”. Ann Pharmacother 32:506PubMedCrossRef

Van Kerrebroeck PE, Heesakkers J, Berriman S, Padmanabhan Aiyer L, Carlsson M, Guan Z (2010) Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract 64:584–593PubMedCrossRef

van KP, Abrams P, Lange R, Slack M, Wyndaele JJ, et al (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 111:249–257CrossRef

Van Kerrebroeck PE, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, Wang JT (2009) Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes 7:13PubMedPubMedCentralCrossRef

Voigt R, Halaska M, Voigt P, Al-Hasan A, Sindlar M (1988) Experience with the conservative treatment of incontinence using the anticholinergic agent propiverin (Mictonorm). Cesk Gynekol 53:180–184PubMed

Wagg A, Dale M, Tretter R, Stow B, Compion G (2013a) Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 64:74–81PubMedCrossRef

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M et al (2013b) Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 61:185–193PubMedCrossRef

Wagg A, Khullar V, Michel MC, Oelke M, Darekar A, Bitoun CE (2014a) Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodyn 33:106–114PubMedCrossRef

Wagg A, Cardozo L, Nitti VW, Castro-Diaz D, Auerbach S, et al (2014b) The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing

Wehnert J, Sage S (1989) Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle. Z Urol Nephrol 82:259–263PubMed

Wiedemann A, Kirschner-Hermanns R, Jacobs AH (2019) Harninkontinenz. In: Maetzler W, Dodel R, Jacobs A (Hrsg) Neurogeriatrie. Springer, Berlin

Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171:2311–2315, quiz

Zinner N, Tuttle J, Marks L (2005) Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 23:248–252PubMedCrossRef

Zinner N, Susset J, Gittelman M, Arguinzoniz M, Rekeda L, Haab F (2006) Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 60:119–126PubMedCrossRef

Zinner NR, Dmochowski RR, Staskin DR, Siami PF, Sand PK, Oefelein MG (2011) Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 30:1214–1219PubMed

Zorzitto ML, Holliday PJ, Jewett MA, Herschorn S, Fernie GR (1989) Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 18:195–200PubMedCrossRef

Titel: OAB und Dranginkontinenz
verfasst von: Andreas Wiedemann
Verlag: Springer Berlin Heidelberg
Buch: Medikamente in der Urologie
Print ISBN: 978-3-662-61491-4

Electronic ISBN: 978-3-662-61492-1

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-61492-1_9

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

OAB und Dranginkontinenz

Zusammenfassung

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Update Urologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Urologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Darf man die Behandlung eines Neonazis ablehnen?

Update Urologie